Study finds known lung cancer oncogenes ALK and ROS1 also drive colorectal cancer
December 17, 2013 · Comments Off
Study shows that shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.
New Crizotinib Side-Effect: Reduced Measures of Kidney Function During Treatment (Recovery After)
November 20, 2013 · Comments Off
A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one of the most commonly used clinical methods.
Study: Redefining the criteria for ALK positive lung cancer
September 10, 2013 · Comments Off
A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug.
With early and obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
August 8, 2013 · Comments Off
When a drug's benefit is obvious in a clinical trial's first or second phase, is the third, costly phase needed? The question is posed in a recent edition of the journal Nature Reviews: Clinical Oncology by Robert C. Doebele, MD, PhD, investigator at the University of Colorado Cancer Center and assistant professor of medical oncology at the CU School of Medicine.
Reality TV meets reality for lung cancer treatment
June 6, 2013 · Comments Off
By Todd Neff It was Memorial Day Weekend 2012, and Ross Camidge, MD, PhD, was...
Multicenter international study confirms low testosterone in 84 percent of lung cancer patients taking crizotinib
April 17, 2013 · Comments Off
Ross Camidge, MD, PhD, and international colleagues confirm low testosterone in a majority of lung cancer patients treated with crizotinib.
Lung cancer patients developing areas of drug-resistance prolong disease control by using focused radiation to weed the garden
November 28, 2012 · Comments Off
KEY POINTS: Pockets of cancer may mutate to gain resistance to targeted therapies It’s possible...
Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
August 28, 2012 · Comments Off
Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.
Chromosomal translocations point the way toward personalized cancer care
August 13, 2012 · Comments Off
A broken chromosome is like an unmoored beansprout circling in search of attachment. If a...
NTRK1: a new oncogene and target in lung cancer
August 13, 2012
ALK alk drug lung cancer ALL amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno biomarkers bladder cancer breast cancer cancer grants cancer research colorado Cancer Survivorship cell signaling clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma metastasis Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge screening skin cancer tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
Today is the day! Enjoy some blueberry pancakes and dress in all blue for Dress in Blue day to increase... http://t.co/LnYh9iT1lW
One last reminder. Wear blue tomorrow for Dress in Blue Day! http://t.co/dNKEDueKNv
In Health Care, Choice Is Overrated. We're glad our patient got the second opinion needed. Hope others can too. http://t.co/3T9CrAj8E2
President Obama has declared March National Colorectal Cancer Awareness Month! Remember to wear blue this Friday... http://t.co/neqgyKCzAC